Addressing Significant Unmet Medical Needs

Developing next-generation therapeutics for diseases representing significant unmet medical needs and a burden to society, patients and their families.

Discovering and Developing New Therapies

We are a clinical-stage pharmaceutical company focused on discovering and developing novel therapies for central nervous system, respiratory, and metabolic diseases of huge unmet need. We are committed to developing better, safer, and more effective treatments that can have a real impact on the lives of our patients.

Better Patient Outcomes
Better Safety Profiles

Using chemical genomics driven technology, we are leveraging scientific innovations to discover and develop new medicines with better therapeutic options for patients in need.

Delivering Safe and Efficacious Treatment Options

Our lead drug candidate, brilaroxazine (RP5063), is in clinical development for multiple unmet neuropsychiatric indications including schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychotic symptoms in Alzheimer’s disease, Parkinson’s disease psychosis, and attention deficit hyperactivity disorder (ADHD).

Learn more about our completed and ongoing clinical trials.

Latest News

Reviva to Participate in the BIO International Convention

CUPERTINO, Calif., May 21, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...

Corporate Presentation